-
Mashup Score: 4Experts Attribute Higher Incidence of Metastatic Prostate Cancer in the US to Fewer PSA Screenings - 3 year(s) ago
More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2ASCO GU 2021: Recommendations From Dr. Jun Gong - 3 year(s) ago
Written by Jun Gong MD
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Felix Y. Feng, MD @felixfengmd @UNSF #ASCOGU21 #Prostat - 3 year(s) ago
Felix Y. Feng, MD, professor of radiation oncology, urology, and medicine from the University of California, San Francisco speaks about the ASCO GU 2021 ab
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PSMA PET Imaging Agent 18F-DCFPyL Enables Better Detection of Localized Metastatic Lesions - 3 year(s) ago
Findings from the phase 3 CONDOR trial support the use of the PSMA PET imaging agent 18F-DCFPyL as the FDA prepares to make a decision on a new drug application regarding its use.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Advanced Clear Cell RCC Has Favorable Response to Belzutifan/Cabozantinib, Early Findings Show - 3 year(s) ago
Investigational agent belzutifan plus cabozantinib was able to control tumor growth in most patients with advanced clear cell renal cell carcinoma in a phase 2 trial.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0In Papillary RCC, Cabozantinib Bests Sunitinib for PFS - 3 year(s) ago
A phase 2 SWOG trial comparing multiple therapies versus sunitinib for papillary renal cell carcinoma revealed superior activity of cabozantinib in this setting.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Efficacy With Enfortumab Vedotin for Cisplatin-Ineligible Urothelial Cancer Shows Unmatched Response Rates - 3 year(s) ago
In patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors, enfortumab vedotin induced the highest response rates seen with any regimen in this setting.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In non-muscle invasive bladder cancer carcinoma in-situ that is not responsive to BCG alone, the addition of N-803 leads to efficacy while maintaining safety.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Brain Metastases Associated With Metastatic RCC Demonstrate Response to Cabozantinib - 3 year(s) ago
Patients with metastatic renal cell carcinoma and brain metastases showed significant intracranial and extracranial responses with cabozantinib use.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Survival Advantage Is Experienced by Patients Receiving Apalutamide Added to ADT for mCSPC - 3 year(s) ago
Compared with androgen-deprivation therapy alone, patients with metastatic castration-sensitive prostate cancer had better outcomes when apalutamide was added to systemic therapy.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say. #ASCOGU21 https://t.co/bM3mJWkGOm